文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

通用型碱基编辑CAR7 T细胞治疗T细胞急性淋巴细胞白血病

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · N Engl J Med · 2025-12-08

在一项1期研究中,9例儿童和2例成人(同情用药)复发或难治性T细胞急性淋巴细胞白血病患者接受碱基编辑抗CD7 CAR(BE-CAR7)T细胞治疗,主要结局为安全性。所有患者第28天达完全形态学缓解但血细胞计数未完全恢复,9例(82%)深度缓解并桥接移植,11例中7例(64%)移植后3至36个月持续缓解。

要点

  • BE-CAR7 T细胞在11例复发或难治性T细胞ALL患者中未导致不可接受的不良事件。
  • 所有患者第28天达完全形态学缓解伴血细胞计数未完全恢复,9例(82%)深度缓解并接受移植。
  • 11例中7例(64%)移植后3至36个月持续缓解,2例出现CD7表达缺失的白血病。

核心结论

  • 通用型BE-CAR7 T细胞使复发或难治性T细胞急性淋巴细胞白血病患者获得白血病缓解,从而使大多数患者成功接受异基因造血干细胞移植。

研究设计与样本

  • 1期研究,入组≤16岁复发或难治性T细胞急性淋巴细胞白血病儿童,在氟达拉滨、环磷酰胺和阿仑单抗清淋后输注BE-CAR7 T细胞;成人经同情用药途径也可入组。
  • BE-CAR7 T细胞为碱基编辑抗CD7 CAR T细胞,经三重C→T脱氨介导敲除TCRαβ、CD52和CD7。
  • 主要结局为安全性;次要结局包括缓解持续时间、无病生存和总生存。
  • 共9例儿童和2例成人(同情用药)接受BE-CAR7 T细胞输注。

主要发现

  • 清淋和BE-CAR7输注未导致不可接受的不良事件,所有患者均可检测到循环CAR7 T细胞。
  • 并发症包括1至4级细胞因子释放综合征、一过性皮疹、多系血细胞减少和机会性感染。
  • 所有患者第28天达完全形态学缓解伴血细胞计数未完全恢复。
  • 9例(82%)达深度缓解(经流式细胞术或聚合酶链反应检测)并接受干细胞移植;2例骨髓可定量微小残留病的患者接受姑息治疗。
  • 移植清除了残留BE-CAR7 T细胞并支持供者来源多系重建;病毒感染再激活频繁,3例移植后出现有临床意义的病毒相关并发症。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, and CD7 have been reported previously. METHODS: In a phase 1 study, we administered BE-CAR7 T cells to children (≤16 years of age) with relapsed or refractory T-cell ALL after they had undergone lymphodepletion with fludarabine, cyclophosphamide, and alemtuzumab. Adults with compassionate-use access arrangements were also eligible. Patients who had remission by day 28 after the BE-CAR7 T-cell infusion proceeded to allogeneic hematopoietic stem-cell transplantation. The primary outcome was safety. Secondary outcomes included duration of remission, disease-free survival, and overall survival. RESULTS: BE-CAR7 T cells were administered to 9 children, as well as to 2 adults who were treated under compassionate-use access arrangements. Lymphodepletion and BE-CAR7 infusions did not lead to unacceptable adverse events, and circulating CAR7 T cells were detected in all the patients. Complications included cytokine release syndrome of grades 1 through 4, transient rashes, multilineage cytopenia, and opportunistic infections. All the patients had complete morphologic remission with incomplete count recovery at day 28. Nine patients (82%) had deep remission (according to flow cytometry or polymerase-chain-reaction assay) that allowed them to proceed to stem-cell transplantation, and 2 patients with quantifiable minimal residual disease in bone marrow received palliative care. Transplantation eliminated remaining BE-CAR7 T cells and supported donor-derived, multilineage reconstitution. Viral reactivations were frequent, and 3 patients had clinically significant virus-related complications after transplantation. Overall, 7 of the 11 patients (64%) who received the investigational therapy were in ongoing remission at 3 to 36 months after transplantation, and leukemia with loss of CD7 expression was documented in 2 patients. CONCLUSIONS: Universal BE-CAR7 T cells induced leukemic remission in patients with relapsed or refractory T-cell ALL, thus allowing successful allogeneic hematopoietic stem-cell transplantation in most of the patients. (Funded by the Medical Research Council and others; ISRCTN Registry number, ISRCTN15323014.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Chiesa R, Georgiadis C, Rashed H, et al. Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2025. PMID: 41363805. doi:10.1056/NEJMoa2505478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。